High-level Expression of the Hc Domain of Clostridium botulinum Neurotoxin Serotype A in Escherichia coli and Its Immunogenicity as an Antigen

Chinese Journal of Biotechnology

Volumn 23, Issue 5, 2007, Pages 812-817

  YU, Yun Zhou ^a   SUN, Zhi Wei ^a   WANG, Shuang ^a   YU, Wei Yuan ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

botulinum neurotoxin; Hc domain; immunogenicity; soluble expression

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY; BOTULINUM TOXIN A; DNA VACCINE; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; BOTULISM; CLOSTRIDIUM BOTULINUM TYPE A; ESCHERICHIA COLI; FEMALE; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BOTULINUM TOXIN TYPE A; BOTULISM; CLOSTRIDIUM BOTULINUM TYPE A; ESCHERICHIA COLI; FEMALE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; T-LYMPHOCYTES; VACCINES, DNA;

CLOSTRIDIUM BOTULINUM; ESCHERICHIA COLI; MUS; PROKARYOTA; CLOSTRIDIUM;

EID: 34948869776     PISSN: 18722075     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1872-2075(07)60052-1     Document Type: Article

References (18)

1. Monteccucco C., and Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol 13 1 (1994) 1-8
2. Montecucco C., Schiavo G., Tugnoli V., et al. Botulinum neurotoxins: mechanism of action and therapeutic applications. Mol Med Today 2 10 (1996) 418-424
3. Schiavo G., Matteoli M., and Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rew 80 2 (2000) 717-766
4. Turton K., Chaddock J., and Acharya K. Botulinum and tetanus neurotoxtins: structure, function and therapeutic utility. Trends Biochem. Sci 27 11 (2002) 552-558
5. Byrne M., and Smith L. Development of vaccines for prevention of botulism. Biochimie 82 9-10 (2000) 955-966
6. LaPenotiere H., Clayton M., and Middlebrook J. Expression of a large nontoxic fragment of botulinum neurotoxin serotype A and its use as a immunogen. Toxicon 33 10 (1995) 1383-1386
7. Clayton M., Clayton J., Brown D., et al. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun 63 7 (1995) 2728-2742
8. Woodward L., Arimitsu H., Hirst R., et al. Expression of Hc subunits from clostridium botulinum type C and D and their evaluation as candidate vaccine antigens in mice. Infect Immun 71 5 (2003) 2941-2944
9. Holley J., Mike E., Margaret M., et al. Cloning, expression and evaluation sub-unit vaccine against clostridium type F toxin. Vaccine 19 2-3 (2001) 288-297
10. Smith L. Development of recombinant vaccines for botulinum toxin. Toxicon 36 11 (1998) 1539-1548
11. Byrne M., Smith T., Montgomery V., et al. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 66 10 (1998) 4817-4822
12. Potter K., Bevins M., Vassilieva E., et al. Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype B, expressed in the methyltrophic yeast Pichia pastoris. Protein Expr Purif 13 3 (1998) 357-365
13. Byrne M., Titball R., Holley J., et al. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris. Protein Expr Purif 18 3 (2000) 327-337
14. Tavallaie M., Chenal A., Gillet D., et al. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS 572 1-3 (2004) 299-306
15. Wang H., and Yin J. Modification and high expression of protective antigen fragment of botulinum neurotoxin serotype A. Chinese Journal of Biotechnology 20 4 (2004) 544-547
16. Sharma S., Zhou Y., and Singh B. Cloning, expression, and purification of C-terminal quarter of the heavy chain of botulinum neurotoxin type A. Protein Expr Purif 45 2 (2006) 288-295
17. Baldwin M., Tepp W., Pier C., et al. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun 73 10 (2005) 6998-7005
18. Romanos M., Makoff A., Fairweather N., et al. Expression of tetanus toxin fragment C in yeast: gene synthesis is required to eliminate fortuitous polyadenylation sites in AT-rich DNA. Nucleic Acids Res 19 7 (1991) 1461-1467